Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
- Conditions
- Interventions
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Mary Crowley Medical Research Center
- Target Recruit Count
- 13
- Registration Number
- NCT02725489
- Locations
- 🇺🇸
Mary Crowley Cancer Research Center, Dallas, Texas, United States
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT02718911
- Locations
- 🇺🇸
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇺🇸Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇧🇪Universitair Ziekenhuis Antwerpen, Edegem, Belgium
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 6
- Registration Number
- NCT02716805
- Locations
- 🇺🇸
Research Facility, New York, New York, United States
A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 56
- Registration Number
- NCT02685826
- Locations
- 🇺🇸
Swedish Medical Center, Seattle, Washington, United States
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦British Columbia Cancer Agency, Vancouver, British Columbia, Canada
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 383
- Registration Number
- NCT02671435
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 423
- Registration Number
- NCT02664935
- Locations
- 🇬🇧
Royal Devon and Exeter Hospital, Exeter, United Kingdom
🇬🇧University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
🇬🇧Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 15
- Registration Number
- NCT02649686
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
🇨🇦BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 58
- Registration Number
- NCT02643303
- Locations
- 🇺🇸
Research Facility, Charlottesville, Virginia, United States
A Study of Durvalumab (MEDI4736) in Esophageal Cancer
- First Posted Date
- 2015-12-24
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Shadia Jalal, MD
- Target Recruit Count
- 39
- Registration Number
- NCT02639065
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Unversity of Iowa Hospital and Clinics, Iowa City, Iowa, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2020-07-07
- Target Recruit Count
- 22
- Registration Number
- NCT02628132
- Locations
- 🇸🇦
King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.